Cost-effectiveness analysis of atezolizumab plus chemotherapy as first-line treatment for patients with advanced nonsquamous non-small-cell lung cancer in China

References

• GBD 2017 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: a systematic analysis for the global burden of disease study 2017. Lancet. 2018;392(10159):1859–1922.
   PubMed Web of Science ®Google Scholar
• Feng RM, Zong YN, Cao SM, et al. Current cancer situation in China: good or bad news from the 2018 global cancer statistics? Cancer Commun. 2019;39(1):22–33.
   PubMed Web of Science ®Google Scholar
• Fitzmaurice C, Akinyemiju TF, Al Lami FH, Global Burden of Disease Cancer Collaboration. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: a systematic analysis for the global burden of disease study. JAMA Oncol. 2018;4(11):1553–1568.
   PubMed Web of Science ®Google Scholar
• Zheng RS, Sun KX, Zhang SW, et al. Report of cancer epidemiology in China, 2015. Zhonghua Zhong Liu Za Zhi. 2019;41:19–28
   Google Scholar
• Wu B, Lu S. The effect of PD-L1 categories-directed pembrolizumab plus chemotherapy for newly diagnosed metastatic non-small-cell lung cancer: a cost-effectiveness analysis. Transl Lung Cancer Res. 2020;9(5):1770–1784.
   PubMed Web of Science ®Google Scholar
• Miller KD, Nogueira L, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. 2019;69(5):363–385.
   PubMed Web of Science ®Google Scholar
• Garon EB, Hellmann MD, Rizvi NA, et al. Five-year overall survival for patients with advanced non-small-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study. J Clin Oncol. 2019;37(28):2518–2527.
   PubMed Web of Science ®Google Scholar
• Guidelines Working Committee of Chinese Society of Clinical Oncology. Guidelines OF Chinese SOCIETY of CLINICAL Oncology (CSCO) NON-SMALL Cell LUNG Cancer 2020. Beijing: People’s Medical Publishing House (2020).
   Google Scholar
• Galetta D, Cinieri S, Pisconti S, et al. Cisplatin/pemetrexed followed by maintenance pemetrexed versus carboplatin/paclitaxel/bevacizumab followed by maintenance bevacizumab in advanced nonsquamous lung cancer: the GOIM (Gruppo Oncologico Italia Meridionale) ERACLE Phase III randomized trial. Clin Lung Cancer. 2015;16(4):262–273.
   PubMed Web of Science ®Google Scholar
• Paz-Ares LG, de Marinis F, Dediu M, et al. PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol. 2013;31(23):2895–2902.
   PubMed Web of Science ®Google Scholar
• Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350–1355.
   PubMed Web of Science ®Google Scholar
• Luke JJ, Ott PA. PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma. Oncotarget. 2015;6(6):3479–3492.
   PubMedGoogle Scholar
• Nishio M, Barlesi F, West H, et al. Atezolizumab plus chemotherapy for first-line treatment of nonsquamous NSCLC: results from the randomized phase 3 impower132 trial. J Thorac Oncol. 2021;16(4):653–664.
   PubMed Web of Science ®Google Scholar
• Saltz LB. Perspectives on Cost and Value in Cancer Care. JAMA Oncol. 2016;2(1):19–21.
   PubMed Web of Science ®Google Scholar
• Liu G, Kang S, Wang X, et al. Cost-effectiveness analysis of atezolizumab versus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer with different PD-L1 expression status. Front Oncol. 2021;11:669195–669205.
   PubMed Web of Science ®Google Scholar
• Bonetti A, Giuliani J. Implications of drugs with rebate in Europe. 2021;Lancet Reg Health Eur. 3:100060–100061.
   PubMedGoogle Scholar
• Liu G, Hu S, Wu J, et al. China guidelines for pharmacoeconomic evaluations. BeiJing: China Market Press (2020).
   Google Scholar
• Eichler HG, Kong SX, Gerth WC, et al. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health. 2004;7(5):518–528.
   PubMed Web of Science ®Google Scholar
• Guyot P, Ades AE, Ouwens MJ, et al. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12(1):9–21.
   PubMed Web of Science ®Google Scholar
• Chen J, Hu G, Chen Z, et al. Cost-effectiveness analysis of pembrolizumab plus axitinib versus sunitinib in first-line advanced renal cell carcinoma in China. Clin Drug Investig. 2019;39(10):931–938.
   PubMed Web of Science ®Google Scholar
• Wu B, Li T, Cai J, et al. Cost-effectiveness analysis of adjuvant chemotherapies in patients presenting with gastric cancer after D2 gastrectomy. BMC Cancer. 2014;14(1):984–994.
   PubMedGoogle Scholar
• Wu B, Ma F. Cost-effectiveness of adding atezolizumab to first-line chemotherapy in patients with advanced triple-negative breast cancer. Ther Adv Med Oncol. 2020;12:1758835920916000.
   Web of Science ®Google Scholar
• Gu X, Zhang Q, Chu YB, et al. Cost-effectiveness of Afatinib, gefitinib, erlotinib and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China. Lung Cancer. 2019;127:84–89.
   PubMed Web of Science ®Google Scholar
• Nafees B, Lloyd AJ, Dewilde S, et al. Health state utilities in non-small cell lung cancer: an international study. Asia Pac J Clin Oncol. 2017;13(5):e195–e203.
   PubMed Web of Science ®Google Scholar
• Wu B, Zhang Q, Sun J. Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma. J Immunother Cancer. 2018;6(1):124–132.
   PubMedGoogle Scholar
• Briggs AH, Weinstein MC, Fenwick EA, et al. Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM modeling good research practices task force working group-6. Med Decis Making. 2012;32:722–732
   Google Scholar
• Lin S, Luo S, Zhong L, et al. Cost-effectiveness of atezolizumab plus chemotherapy for advanced non-small-cell lung cancer. Int J Clin Pharm. 2020;42(4):1175–1183.
   PubMed Web of Science ®Google Scholar
• Yang Z, Zhu Y, Xiang G, et al. First-line atezolizumab plus chemotherapy in advanced non-squamous non-small cell lung cancer: a cost-effectiveness analysis from China. Expert Rev Pharmacoecon Outcomes Res. 2021;21(5):1061–1067.
   PubMed Web of Science ®Google Scholar